RFX5 Antibody - BSA Free

RFX5-Antibody-Immunohistochemistry-NBP1-86041-img0011.jpg

Immunohistochemistry-Paraffin: RFX5 Antibody [NBP1-86041] - Staining of human Duodenum shows strong nuclear positivity in glandular cells.

Immunohistochemistry-Paraffin: RFX5 Antibody [NBP1-86041] - Staining of human Fallopian tube shows strong nuclear positivity in glandular cells.

Immunohistochemistry-Paraffin: RFX5 Antibody [NBP1-86041] - Staining of human Kidney shows strong nuclear positivity in cells in tubules and in glomeruli.

Immunohistochemistry-Paraffin: RFX5 Antibody [NBP1-86041] - Staining of human Lymph node shows strong nuclear positivity in non-germinal center and germinal center cells.

nbp1-86041_rabbit-polyclonal-rfx5-antibody-20920231721151.jpg

Analysis in human cell line HDLM-2.

RFX5 is a positive regulator of KDM4A expression in HCC. (A) KDM4A expression levels were assessed in FLAG-RFX5-transfected HepG2 cells via QRT-PCR analysis. (B) KDM4A expression levels were assessed in shRNA targeting RFX5-transfected HepG2 cells via QRT-PCR analysis. (C) KDM4A protein expression levels were determined in MHCC-97H and HepG2 cells transduced with lentiviral FLAG-RFX5 or sgRNA targeting RFX5 via Western blot analysis. (D) The correlation between RFX5 and KDM4A mRNA expressions in HCC patients derived from TCGA LIHC dataset. (E) The correlation of KDM4A protein expression status determined by IHC analysis with overall survival time (OST). (F) The correlation of KDM4A mRNA expression level determined by RNAseq in TCGA LIHC dataset with OST. (G) Immunohistochemistry analysis was used to quantify the amount of KDM4A protein in HCC tumor tissues and adjacent non-tumor tissues was determined (N−, less than 5% of tumor cells stained positive; N+, 5–30% of tumor cells stained positive; N++, 31–50% of tumor cells stained positive; N+++, > 51% of tumor cells stained positive.). (H) IHC staining of RFX5 and KDM4A in the same cancer nest. (I) The co-expression of RFX5 and KDM4A in HCC tissues was determined by the immunofluorescence staining. The white arrows pointed HCC cells which co-expressed RFX5 and KDM4A. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/32883983), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

RFX5 is a positive regulator of KDM4A expression in HCC. (A) KDM4A expression levels were assessed in FLAG-RFX5-transfected HepG2 cells via QRT-PCR analysis. (B) KDM4A expression levels were assessed in shRNA targeting RFX5-transfected HepG2 cells via QRT-PCR analysis. (C) KDM4A protein expression levels were determined in MHCC-97H and HepG2 cells transduced with lentiviral FLAG-RFX5 or sgRNA targeting RFX5 via Western blot analysis. (D) The correlation between RFX5 and KDM4A mRNA expressions in HCC patients derived from TCGA LIHC dataset. (E) The correlation of KDM4A protein expression status determined by IHC analysis with overall survival time (OST). (F) The correlation of KDM4A mRNA expression level determined by RNAseq in TCGA LIHC dataset with OST. (G) Immunohistochemistry analysis was used to quantify the amount of KDM4A protein in HCC tumor tissues and adjacent non-tumor tissues was determined (N−, less than 5% of tumor cells stained positive; N+, 5–30% of tumor cells stained positive; N++, 31–50% of tumor cells stained positive; N+++, > 51% of tumor cells stained positive.). (H) IHC staining of RFX5 and KDM4A in the same cancer nest. (I) The co-expression of RFX5 and KDM4A in HCC tissues was determined by the immunofluorescence staining. The white arrows pointed HCC cells which co-expressed RFX5 and KDM4A. Image collected and cropped by CiteAb from the following open publication (//pubmed.ncbi.nlm.nih.gov/32883983), licensed under a CC-BY license. Not internally tested by Novus Biologicals.

ChIP-Exo-Seq composite graph for Anti-RFX5 tested in K562 cells. Strand-specific reads (blue: forward, red: reverse) and IgG controls (black: forward, grey: reverse) are plotted against the distance from a composite set of reference binding sites. The antibody exhibits robust target enrichment compared to a non-specific IgG control and precisely reveals its structural organization around the binding site. Data generated by Prof. B. F. Pugh's Lab at Cornell University.

• Reactivity: Hu
• Applications: WB, IHC, ChIP
• Clonality: Polyclonal
• Host: Rabbit
• Conjugate: Unconjugated
• Format: BSA Free

RFX5 Antibody - BSA Free Summary

• Immunogen: This antibody was developed against Recombinant Protein corresponding to amino acids: ARRLGGRGQSKYCYSGIRRKTLVSMPPLPGLDLKGSESPEMGPEVTPAPRDELVEAACALTCDWAERILKRSFSSIVEVARFLLQQHLISARSAHAHVLKAMGLAEEDEHAPRERSSKPKNGLENPEGGAHKKPERLAQPPKDLEART
• Isotype: IgG
• Clonality: Polyclonal
• Host: Rabbit
• Gene: RFX5
• Purity: Affinity purified

Applications/Dilutions

• Dilutions:
  • Chromatin Immunoprecipitation-exo-Seq 1-10ug per reaction
  • Immunohistochemistry 1:50 - 1:200
  • Immunohistochemistry-Paraffin 1:50 - 1:200
  • Western Blot 0.04-0.4 ug/ml
• Application Notes: For IHC-Paraffin, HIER pH 6 retrieval is recommended.
• Control Peptide:

  RFX5 Protein (NBP1-86041PEP)

Reactivity Notes

Immunogen displays the following percentage of sequence identity for non-tested species: Mouse (88%), Rat (89%)

Packaging, Storage & Formulations

• Storage: Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
• Buffer: PBS (pH 7.2) and 40% Glycerol
• Preservative: 0.02% Sodium Azide
• Purity: Affinity purified

Alternate Names for RFX5 Antibody - BSA Free

• DNA-binding protein RFX5
• Regulatory factor X 5
• regulatory factor X, 5 (influences HLA class II expression)

Background

RFX5 is the regulatory gene responsible for human MHC class II deficiency. Patients with this disease exhibit a characteristic defect in the binding of a nuclear factor, RFX, to the X box motif of MHC class II promoters. RFX5 is the 75 kDa subunit of the RFX complex which is absolutely essential and highly specific for regulating MHC class II gene expression and control of the immune response. RFX5 is a protein consisting of 616 amino acids.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for RFX5 Antibody (NBP1-86041)(1)

Publication using NBP1-86041

• Chen DB, Xie XW, Zhao YJ et al. RFX5 promotes the progression of hepatocellular carcinoma through transcriptional activation of KDM4A Sci Rep 2020-09-03 [PMID: 32883983] (IF/IHC, Human)

Bioinformatics

• Gene Symbol: RFX5